UBDRS
84% margin diagnostic-therapeutic — targets cellular repair pathways via UV biophoton resonance
Phase 1 (Diagnostic): Maps ultra-weak UV biophoton emission from the body surface using PMT array spectroscopy, generating a cellular health map identifying regions of disrupted cellular coherence. Phase 2 (Therapeutic): Delivers targeted UV photon pulses at mapped coordinates, stimulating cellular repair pathways and coherence restoration. Applications include studying age-related biophoton emission changes, oxidative stress markers, and UV photobiomodulation efficacy.
The UBDRS (UV Biophoton Disease Reversal System) combines diagnostic biophoton emission spectroscopy with targeted UV therapeutic delivery. In the diagnostic phase, a photomultiplier tube array measures ultra-weak UV biophoton emission from the skin surface — coherent light spontaneously emitted by healthy cells differs spectrally and spatially from disease-state emission. The therapeutic phase uses these emission maps to precisely target UV photon delivery at identified cellular populations, inducing photobiomodulation at the UV range (200–400 nm) to stimulate cellular repair mechanisms.
- UV PMT array (16-channel, 200–400 nm sensitivity)
- Ultra-weak light emission measurement system (single-photon sensitivity)
- Targeted UV therapeutic delivery array (200–400 nm)
- Emission mapping software (cellular coherence visualization)
- Motorized scanning gantry (full-body coverage)
- Clinical reporting module (session + trend analysis)
| Component | Est. Cost |
|---|---|
| UV PMT array (16-channel spectroscopy) | $2,400 |
| Targeted UV therapeutic delivery array | $1,800 |
| Motorized scanning gantry | $1,200 |
| Emission mapping workstation + software | $1,100 |
| Shielded measurement enclosure | $880 |
| Power + control electronics | $361 |
Supplier names not shown on this page. Full sourcing guide included with institutional purchase. Volume pricing available — see note below.